Platelet Derived Growth Factor Receptor ß (PDGFRß) Imaging in Cardiac Fibrosis
This study uses a special PET imaging technique to look at how the heart changes after a heart attack, specifically focusing on a protein that may be involved in heart scarring and weakness. Researchers want to understand why some patients recover well after a heart attack while others develop heart failure. The study involves imaging scans and takes place over several visits.
Key Objective: This research may help identify which heart attack patients are at risk for developing heart failure, potentially leading to better treatments and monitoring strategies.
Who to Consider: Patients who have recently had a ST-elevation myocardial infarction (a type of heart attack) and are interested in advancing heart disease research should consider enrolling.
Trial Parameters
Brief Summary
An observational, cross-sectional, longitudinal, microdosing Position Emission Tomography (PET) imaging study to investigate platelet derived growth factor receptor beta (PDGFRß) expression in the heart of patients with high or low risk of heart failure after a ST-Elevation Myocardial Infarction (STEMI) after a percutaneous coronary intervention (PCI) with a stent procedure, as well as in patients with heart failure with preserved ejection fraction (HFpEF) and healthy individuals.
Eligibility Criteria
Inclusion Criteria: * Willing and able to give written informed consent for participation in the trial and able to comply with all trial procedures and requirements. * Male or female participant aged 40 to 70 years, inclusive, at the screening visit. * Women of childbearing potential must practice abstinence from heterosexual intercourse or must agree to use a highly effective method of contraception. Cohort-specific inclusion criteria: Cohort 1, STEMI high-risk patients: * NT-proBNP \>500 pg/mL within 48 hrs after PCI * Post-PCI Thrombolysis In Myocardial Infarction (TIMI) score \<3. * No previous history of coronary artery disease or heart failure. Cohort 2, STEMI low-risk patients * NT-proBNP \<500 pg/mL within 48 hrs after PCI * Post-PCI TIMI score 3. * No previous history of coronary artery disease or heart failure. Cohort 3 (HFpEF patients) * Presence of signs and symptoms of HF * Ejection Fraction ≥50% * Elevated levels of natriuretic peptides (NT-proBNP≥125pg/mL) * At least one